| PATENT NUMBER | This data is not available for free |
| PATENT GRANT DATE | June 15, 2004 |
| PATENT TITLE |
Humanized and chimeric N-terminal amyloid beta-antibodies |
| PATENT ABSTRACT | The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A.beta. in the brain of a patient Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A.beta. and antibodies binding to the same |
| PATENT INVENTORS | This data is not available for free |
| PATENT ASSIGNEE | This data is not available for free |
| PATENT FILE DATE | November 28, 2000 |
| PATENT REFERENCES CITED |
Walker et al. (Jul. 1994) "Labeling of Cerebral Amyloid in Vivo with a Monoclonal Antibody." Journal of Neuropathology and Experimental Neurology 53(4): 377-383.* Szendrei et al. (Apr. 1996) "The effects of aspartic acid-bound isomerization on in vitro properties of the amyloid b-peptide as modeled with N-terminal decapeptide fragments." Int. J. Peptide Protein Res. 47(4): 289-296.* Akiyama et al. (Feb. 15, 1999) "Occurance of the Diffuse Amyloid b-Protein (Ab) Deposits with Numerous Ab-Containing Glial Cells in the Cerebral Cortex of Patients with Alzheimer's Disease." GLIA 25(4): 324-331.* Johnstone et al. (Mar. 27, 1996) "Nuclear and Cytoplasmic Localization of the b-Amyloid Peptide (1-43) in Transfected 293 Cells." Biochemical and Biophysical Research Communications 220(3): 710-718.* U.S. patent application Ser. No. 09/724,842, Chalifour et al., filed Nov. 28, 2000. U.S. patent application Ser. No. 09/441,410, Solomon et al., filed Nov. 16, 1999. Andersen et al., "Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease?," Neurology, 45:1441-1445 (1995). Associated Press, "Immune cells may promote Alzehimer's, a study finds," The Boston Globe (Apr. 13, 1995). Bard et al., "Peripherally administered antibodies against amyloid .beta.-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease," Nature Medicine, 6(8):916-919 (2000). Barrow, et al., "Solution Conformations and aggregational Properties of Synthetic Amylold Beta-Peptides of Alzheimer's Disease. Analysis of Circular Dichroism Specta" J. Mol.Biol., 225(4): 1075-1093 (1992). Bauer et al., "Interleukin-6 and .alpha.-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices," FEBS Letters, 285(1):111-114 (1991). Beasley, "Alzheimer's traced to proteins caused by aging." Reuters, Apr. 20, 2001 7:56 PM ET. Bercovici et al., "Chronic Intravenous Injections of Antigen Induce and Maintain Tolerance in T Cell Receptor-Transgenic Mice," Eur. J. Immunol. 29:345-354 (1999). Bickel, et al., "Site Protected, Cationized Monoclonal Antibody Against Beta Amyloid as a Potential Diagnostic Imaging Technique for Alzheimer's Diseases," Soc. for Neuroscience Abstracts 18;764 (1992). Blass, John P., "Immunologic Treatment of Alzheimer's Disease," New England J. Medicine, 341(22):1694 (1999). Bodmer et al., "Transforming Growth Factor-Beta Bound to Soluble Derivatives of the Beta Amyloid Precursor Protein of Alzheimer's Disease," Biochem. Biophys. Res, Comm., 171(2):890-897 (1990). Borchelt et al., "Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins," Neuron, 19:939-945 (1997). Boris-Lawrie et al., "Recent advances in retrovirus vector technology," Cur. Opin. Genet Develop., 3: 102-109 (1993). Brice et al., "Absence of the amyloid precursor protein gene mutation (APP717 :Val->lle) in 85 cases of early onset Alzheimer's disease," J. Neurology, Neurosurg. Psychiatry, 56:112-115 (1993). Cameron, "Recent Advances in Transgenic Technology," Molecular Biotechnology, 7:253-265 (1997). Caputo et al., "Therapeutic approaches targeted at the amyloid proteins in Alzheimer's disease," Clin. Neuropham., 15:414A-414B (1992). Chao et al., "Transforming Growth Factor-.beta. Protects human Neurons Against .beta.-Amyloid-Induced Injury," Soc. Neurosci. Abstracts, 19:513-7 (1993). Chapman, Paul F., "Model behavior," Nature, 408:915-916 (2000). Chen, et al. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature, 408(6815):975-9 (2000). Chen et al, "An Antibody to .beta. Amyloid Precursor Protein Inhibits Cell-substraturn Adhesion in Many Mammalian Cell Types," Neuroscience Letters 125:223-226 (1991). Chung et al. "Uptake, Degradation, and Release of Fibrillar and Soluble Forms of Alzheimer's Amyloid .beta.-Peptide by Microglial Cells," J. Biol. Chem., 274-(45):32301-32308 (1999). Coloma et al., "Transport Across the Primate Blood-Brain Barrier of a Genetically Engineered Chimeric Monoclonal Antibody to the Human Insulin Receptor," Pharm. Res., 17:266-274 (2000). Cordell, B., ".beta.-Amyloid formation as a potential therapeutic target for Alzheimer's disease," Ann. Ray. Pharmacol. Toxicol., 34:69-89 (1994). Costa et al., "Immunoassay for transthyretin variants associated with amyloid neuropathy," Scand. J. Immunol., 38:177-182 (1993). Daly, et al., "Detection of the membrane-retained carboxy-terminal tail containing polypeptides of the amyloid precursor protein in tissue from Alzheimer's Disease brain," Life Sci., 63-2121-2131 (1996). Demattos et al., "Peripheral Anti A.beta. Antibody Alters CNS And Plasma A.beta. Clearance and Decreases Brain A.beta. Burden in a Mouse Model of Alzheimer's Disease," Proc. Natl. Acad.Sci. USA. 10.1973/pnas, 151261398 (2001). Du, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology. 57(5):801-5 (2001). Duff et al., "Mouse model made," Nature, 373: 476-477 (1995). Dumery et al., ".beta.-Amyloid protein aggregation: its implication in the physiopathology of Alzheimer's disease," Pathol. Biol., 48:72-85 (2001). Elan, "Elan and AHP Provide an Update on the Phase 2A Clinical Trial of AN-1792," Press Release. (Jan. 28, 2002). Elan, "Elan and Wyeth Provide Update on Status of Alzheimer's Collaboration," Press Release (Mar. 1, 2002). Elizan et al., "Antineurofilament antibodies in a postanoephalltic and Idlopathic Parkinson's disease," J. Neurol. Sciences, 59:341-347 (1983). Esiri, "Is an effective immune intervention for Alzheimer's disease in prospect?," Trends In Pharm. Sci., 22:2-3 (2001). Felsenstein et al., "Processing of the .beta.-amyloid precursor protein carrying the familial, Dutch-type, and a novel recombinant C-terminal mutation," Neuroscience Letters, 152:185-189 (1993). Felsenstein et al., "Transgenic Rat and In-Vitro Studies of B-Amyloid Precursor Protein Processing;" Alzheimer's and Parkinson's Diseases, Hanin et al. Ed., pp 401-409, Plenum Press, New York, (1995). Finch et al., "Evolutionary Prespectives on Amyloid and Inflammatory Features of Alzheimer Disease," Neurobiology of Aging, 17(5):809-815 (1996). Fisher et al., "Expression of the amyloid precursor protein gene in mouse oocytes and embryos," PNAS, 88:1779-1782 (1991). Flanders et al., "Altered expression of transforming growth factor-.beta. in Alzheimer's disease," Neurology, 45:1561-1569 (1995). Frenkel et al., "Generation of auto-antibodies towards Alzheimer's disease vaccination," Vaccine, 19:2615-2619 (2001). Frenkel et al., "Immunization against Alzheimer's .beta.-amyloid plaques via EFRH phage administration," PNAS USA, 97:11455-11459 (2000). Frenkel et al., "N-terminal EFRH sequence of Alzheimer's .beta.-amyloid peptide represents the epitope of its anti-aggregating antibodies," J. of Neroimmunology, 88:85-90 (1998). Frenkel et al., "High affinity binding of monoclonal antibodies to the sequential epitope EFRH of .beta.-amyloid peptide is essential for modulation of fibrillar aggregation," J. of Neuroimmunology, 95:136-142 (1999). Frenkel, et al., "Modulation of Alzheimer's .beta.-amyloid neurotoxicity by site-directed single chain antibody," J. of Neuroimmunology, 106:23-31 (2000). Friedland et al., "Development of an anti-A.beta. monoclonal antibody for in vivo Imaging of amyloid angiopathy in Alzheimer's disease," Mol. Neurology, 9:107-113 (1994). Friedland, et al., "Neuroimaging of Vessel Amyloid in Alzheimer's Disease," in Cerebrovascular Pathology in Alzheimer's Disease, eds. de la Torre and Hachinski, New York Academy of Sciences, New York, New York (1997). Games et al., "Alzheimer-type neuropathology in transgenic mice overexpressing V717F .beta.-amyloid precursor protein," Nature, 373(6514): 523-527 (1995). Games et al., "Prevention and Reduction of AD-type Pathology in PDAPP Mice Immunized with A.beta..sub.242," Annals of the New York Academy of Science 820:274-84 (2000). Gandy et al., "Amyioldogenesis in Alzheimer's disease: some possible therapeutic opportunities," TIPS, 13:108-113 (1992). Gardella et al., "Intact Alzheimer amyloid precursor protein (APP) is present in platelet membranes and is encoded by platelet mRNA," Biochem. Biophys. Res. Comm., 173:1292-1298 (1990). Gaskin et al., "Human antibodies reactive with beta-amyloid protein in Alzheimer's disease," J. Exp. Med., 177:1181-1186 (1993). Geddes, "N-terminus truncated .beta.-amyloid peptides and C-terminus truncated secreted forms of amyloid precursor protein: distinct roles in the pathogenesis of Alzheimer's disease," Neurobiology of Aging, 20:75-79 (1999). Giulian, et al., "The HHQK Domain of b-Amyloid Provides a Structural Basis for the Immunopathology of Alzheimer's Disease," Journal of Biological Chem., 273:29719-29726 (1998). Glenn et al., "Skin immunization made possible by cholera toxin," Nature, 391: 851 (1998). Glenner et al., "Alzheimer's Disease and Downs Syndrome: Sharing of A Unique Cerebrovascular Amyloid Fibril Protein," Biochemical and Biophysical Research Communications, 122(3): 1131-1135 (1984). Glenner et al., "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein," Biochemical and Biophysical Research Communications, 120(3): 885-890 (1994). Goate et al., "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease," Nature, 349:704-706 (1991). Gonzales-Fernandez et al., "Low antigen dose favors selection of somatic mutants with hallmarks of antibody affinity maturation," Immunology, 83:149-153 (1998). Gortner, Outlines of Biochemistry, pp. 322-323, John Wiley & Sons, Inc., New York (1949). Gozes est al., "Neuroprotective strategy for Alzheimer disease: Intranasal administration of a fatty neuropeptide," PNAS USA, 93:427-432 (1996). Gravina et al., "Amyloid .beta. Protein (A.beta.) in Alzheimer's Disease," J. Biol. Chem., 270(13):7013-7016 (1995). Grubeck-Loebenstein, et al., "Immunization with .beta.-amyloid: could T-cell activation have a harmful effect?", TINS, 23:114 (2000). Gupta et al., "Differences in the immunogenicity of native and formalized cross reacting material (CRM197) of diptheria toxin in mice and guinea pigs and their implications on the development and control of diphtheria vaccine based on CRMs," Vaccine, 15(12/13); 1341-1343 (1997). Haass et al, "Amyloid beta-peptide is produced by cultured cells during normal metabolism," Nature, 359(6393):322-5 (1992). Haga et al., "Synthetic Alzheimer amyloid .beta./A4 peptides enhance production of complement C3 component by cultured microglial cells," Brain Research, 601:88-94 (1983). Hanan and Solomon, "Inhibitory effect of monoclonal antibodies on Alzheimer's .beta.-amyloid peptide aggregation," Int. J. Exp. Clin. Invest., 3:130-133 (1996). Hanes et al., "New advances in microsphere-based single-dose vaccines," Advanced Drug Delivery Reviews, 28:97-119 (1997). Hardy, "Amyloid, the presenilins and Alzheimer's disease," TINS, 20(4): 154-159 (1997). Hardy, John, "New Insights Into the Genetics of Alzheimer's Disease," Annals of Med., 28:255-258 (1998). Harigaya, et al., "Modified amyloid .beta. protein ending at 42 or 40 with different solubility accumulates in the brain of Alzheimer's disease," Biochem. Biophys. Res. Comm., 211:1015-1022 (1998). Harrington et al., "Characterization of an epitope specific to the neuron-specific isoform of human enolase recognized by a monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of .beta. / A4-protein," Biochimica Biophysica Acta, 1158:120-128 (1993). Hazama, et al., "Intranasal Immunization Against Herpes Simplex Virus Infection by Using a Recombinant Glycoprotein D Fused With Immunomodulating Proteins, the B Subunit of Escherichia coli Heat-Labile Enterotoxin and Interleukin-2", Immunology, vol. 75: 843-849 (1993). Helmuth, L., "Further Progress on a .beta.-Amyloid Vaccine," Science, 289-375 (2000). Hilbich et al., :Human and rodent sequence analogs of Alzheimer's amyloid .beta.A4 share similar properties and can be solubilized in buffers of pH 7.4, Eur. J. Biochem., 201:61-69 (1991). Hbiao et al., "Correlative Memory Deficits, A.beta. Elevation, and Amyloid Plaques in Transgenic Mice," Science, 274: 99-102 (1988). Huberman et al., "Correlation of cytokine secretion by mononuclear cells of Alzheimer's patients and their disease stage," J. Neuroimmunology, 52:147-152 (1994). Hyman et al., "Molecular Epidemiology of Alzheimer's Disease," N. E. J. Medicine, 333(19):1283-1284 (1995). Ikeda, et al., "Immunogoid labeling of cerebrovascular and nauritic plaque amyloid fibrils In Alzheimer's disease with an anti-.beta. protein monoclonal antibody," Lab. Invest., 57:446-449 (1987). Itagaki et al., "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease," J. Neuroimmunology, 24:173-182 (1989). Iwatsubo et al., "Visualization of A.beta.42(43) and A.beta.40 in Senile Plaques with End-Specific A.beta. Monoclonals: Evidence That an Initially Deposited Species in A.beta. 42(43)," Neuron, 13:45-53 (1994). Jansen et al., "Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity," Immun. Rev., 62: 185-216 (1982). Janus, et al, A beta peptide Immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease, Nature. 408(6815):979-82 (2000). Jen, et al., "Preparation and purification of antisera against different regions or isoforms of b-amyloid precursor protein," Brain Research Protocols, 2:23-30 (1997). Joachim et al., "Antibodies to Non-beta Regions of the Beta-amyloid Precursor Protein Detect a Subset of Senile Plaques," Am. J. of Pathology 138:373-384 (1991). Kalaria, R. N., "Serum amyloid P and related molecules associated with the acute-phase response in Alzheimer's disease," Res. Immunology, 143:637-641 (1992). Katzav-Gozansky et al., "Effect of monoclonal antibodies in preventing carboxypeptidase A aggregation," Biotechnol. Appl. Biochem., 23:227-230 (1996). Kawabata et al., "Amyloid plaques, neurofibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C-terminal fragment of human amyloid precursor protein," Nature, 354:476-478 (1991). Kida, et al., "Early amyloid-.beta. deposits show different immunoreactivity to the amino- and carboxy-terminal regions of b-peptide in Alzheimer's disease and Down's syndrome brain," Neuroscience Letters, 193:105-108 (1995). Konig et al., "Development and Characterization of a Monoclonal Antibody 369,2B Specific for the Carboxyl-Terminus of the .beta.A4 Peptide," Annals of NY Acad. Sci., 777:344-355 (1996). Lampert-Etchells et al., "Regional Localization of Cells Containing Complement Q1q and C4 mRNAs in the Frontal Cortex During Alzheimer's Disease," Neurodegeneration, 2:111-121 (1993). Langer, "New Method of Drug Delivery," Science, 249: 1527-1532 (1990). Lannfelt et al., "Alzheimer's disease: molecular genetics and transgenic animal models," Behavioural Brain Res. 57:207-213 (1993). Lansbury, Peter T., "Inhibition of amyloid formation: a strategy to delay the onset of Alzheimer's disease," Curr. Ops.in Chemical Biology, 1:260-267 (1997). Lemere et al., "Mucosal Administration of A.beta. Peptide Decreases Cerebral Amyloid Burden in Pd-App Transgenic Mice," Society for Neuroscience Abstracts, vol. 25, part 1, Abstract 519.6, 29th Annual Meeting, (Oct. 23-28, 1999). Lemere, et al., "Nasal A.beta. treatment induces anti-A.beta. antibody production and decreases cerebral amyloid burden in PD-APP mice," Annals of the NY Acad. Sci., 920:328-331 (2000). Li and Solomon, "Thermal Stabilization of Carboxypeptidase A as a Function of PH and Ionic Milleu," Biochem. Mol. Biol. Int., 43(3):601-611 (1997). Livingston et al., "The Hepatitis B Virus-Specific CTL Responses Induced in Humans by Liopeptide Vaccination Are Comparable to Those Elicited by Acute Viral Infection," J. Immunol., 159: 1383-1392 (1997). Lopez, et al., "Serum auto-antibodies in Alzheimer's disease," Acta, Neurol, Scand., 84:441-444 (1991). Majocha et al., "Development of a Monoclonal Antibody Specific for .beta./A4 Amyloid in Alzheimer's Disease Brain for Application to In Vitro Imaging of Amyloid Angiopathy," The J. of Nuclear Med. 33:2184-2189 (1992). Mak, et al., "Polyclonals to b-amyloid (1-42) identify most plaque and vascular deposits in Alzheimer cortax, but the striatum," Brain Research, 667:138-142 (1994). Mann, et al., "Amyloid .beta. protein (A.beta.) deposition in chromosome 14-linked Alzheimer's disease: Predominance of A.beta..sub.42(42)," Annals of Neurology, 40:149-156 (1996). Mann, et al., "The extent of amyloid deposition in brain in patients with Down's syndrome does not depend upon the apollpoprotein E genotype," Neuroscience Letters, 196:105-108 (1995). Masters et al., "Amyloid Plaque core protein in Alzheimer Disease and Down Syndrome," Proc. Natl. Acad. Sci. USA 82:4245-4249 (1985). Mattson, Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenio derivatives, Physiol Rev. 77(4):1081-132 (1997). McGee et al., "The encapsulation of a model protein in poly (D, I. lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibillty," J. Micro. Encap., 14(2): 197-210 (1997). McGeer, et al., "Immunohistochemical localization of beta-amyloid precursor protein sequences in Alzheimer and normal brain tissue by light and electron microscopy," J. of Neuroscience Res., 31:428-442 (1992). McNeal et al., "Stimulation of local Immunity and protection in mice by intramuscular Immunization with triple- or double-layered rotavirus particles and CQS-21," Virology, 243:158-166 (1998). Meda et al., "Activation of microglial cells by .beta.-amyloid protein and interferon-.gamma.," Nature, 374:847-850 (1995). Mena, et al., "Monitoring pathological assembly of tau and .beta.-amyloid proteins in Alzheimer's disease," Acta Neuropathol., 89:50-56 (1995). Merluzzi, et al. Humanized antibodies as potential drugs for therapeutic use. Adv Clin Path. 4(2):77-85 (2000). Miller et al., "Antigen-driven Bystander Suppression after Oral Administration of Antigens," J. Exp. Med., 174:791-798 (1991). Morgan, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimers's disease, Nature. 408(6815):982-5 (2000). Mori et al., "Mass Spectrometry of Purified Amyloid .beta. Protein in Alzheimer's Disease," J. Biol. Chem., 267(24):17082-17088 (1992). Morris, et al., "The Consortium to Establish a registry for Alzheimer's Disease (CERAD)," Neurology, 39:1159-65 (1989). Murphy et al., "Development of a Monoclonal Antibody Specific for the COOH-Terminal of .beta.-Amyloid 1-42 and its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," Am. J. Pathology, 144(5):1082-1088 (1994). Nakamura et al., "Histopathological studies on senile plaques and cerebral amyloid angiopathy in aged cynomologus monkeys," Exp. Anim., 43:711-718 (1995). Nakamura, et al., "Carboxyl end-specific monoclonal antibodies to amyloid .beta. protein (A.beta.) subtypes (A.beta.40 and A.beta.42(43) differentiate Ab in senile plaques and amyloid angiopathy in brains of aged cynomolgus monkeys," Neuroscience Letters, 201:151-154 (1995). Nakayama et al., "Histopathological studies of senile plaques and cerebral amyloidosis in cynomolgus monkeys," J. of Med. Primatology, 27:244-262 (1998). Nathanson et al., "Bovine Spongiform Encephalopathy (BSE): Causes and Consequences of a Common Source Epidemic," Am. J. Epidemiol., 145(11): 959-989 (Jun. 1, 1997). New York Times National, "Anti-Inflammatory Drugs May Impede Alzheimer's," (Feb. 20, 1994). Newcombe and Cohen, "Solubility characteristics of isolated amyloid fibrils," Biochim. Biophys. Acta, 104:480-486 (1965). Niemann, "Trangenic farm animals get off the ground," Transcenic Research 7:73-75 (1998). Pardridge et al., "Chimeric peptides as a vehicle for peptide pharmaceutical delivery through the blood-brain barrier," Biochem. Biophys. Res. Comm., 146:307-313 (1987). Paresce et al., "Microglial cells influence aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor," Neuron, 17:553-565 (Sep. 1996). Paul et al., "Transdermal Immunization with large proteins by means of ultradeformable drug carriers," Eur. J. Immunol., 25: 3521-3524 (1995). Peterson, et al., " Recombinant Antibodies: Alternative Strategies for Developing and Manipulating Murine-Derived Monoclonal Antibodies," Laboratory Animal Science, 46(1):8-14 (1996). Philippe, et al. "Generation of a monoclonal antibody to the carboxy-terminal domain of tau by immunization with the amino-terminal domain of the amyloid precursor protein," J. of Neuroscience Res., 46:709-719 (1998). Prieels et al., "Synergistic adjuvants for vaccines," Chemical Abstracts, 120(8): p. 652, col. 1, abstract 86406t (1994). Quon et al., "Formation of .beta.-Amyloid protein deposits in brains of transgenic mice," Nature, 352:239-241 (1991). Raso, "Immunotherapy of Alzheimer's Disease," Immunotherapy Weekly, Abstract (Apr. 2, 1998). Rogers et al., "Complement activation by .beta.-amyloid in Alzheimer Disease," PNAS, 89:1-5 (1992). Rossor et al., "Alzheimer's Disease Families with Amyloid Precursor Protein Mutations," Annals of New York Academy of Sciences, 695:198-202 (1993). Rudinger, "Characteristics of the Amino Acids as Components of a Peptide Homone Sequence," In Peptide Hormones, J.A. Parson, ed. University Park Press, Baltimore, pp 1-7 (1976). Saido et al., "Spatial Resolution of Fodrin Proteolysis in Postischemic Brain," J. Biol. Chem., 268(33):25239-25243 (1993). Saido et al., "Spatial Resolution of the Primary .beta.-Amyloidogenic Process Induced in Postischemic Hippocampus," J. Biol. Chem., 269(21):15253-15257 (1994). Saito et al., "Vector-mediated delivery of .sup.125 I-labeled .beta.-amyloid peptide Ab.sup.1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A.beta..sup.1-40 vector complex," PNAS USA, 92:10227-10231 (1995). Saitoh, N. and K. Imal, "Immunological analysis of Alzheimer's disease using anti- .beta.-protein monoclonal antibodies," Sepporo Med. J., 60:309-320 (1991). Sasaki et al., "Human choroid plexus is an uniquely involved area of the brain in amyloidosis: a histochemical, Immunohistochemical and ultrastructural study," Brain Res., 755:193-201 (1997). Schenk et al., "Immunization with amyloid-.beta. attenuates Alzheimer-disease-like pathology in the PDAPP mouse," Nature, 400:173-177 (1999). Schenk, et al, Immunotherapy with beta-amyloid for Alzheimer's disease: a new frontier, DNA Cell Biol. 20(11):679-81 (2001). Schenk et al., "Therapeutic Approaches Related to Amyloid-.beta. Peptide and Alzheimer's Disease," J. Med. Chem., 38(21):4141-4154 (1995). Schenk, et al., ".beta.-peptide immunization," Arch. Nuerol., 57:934-938 (2000). Selkoe, "Alzheimer's Disease: A Central Role for Amyloid," J. Neuropathol. Exp. Neurol., 53(5): 438-447 (1994). Selkoe, "Physiological production of the .beta.-amyloid protein and the mechanism of Alzheimer's disease," Trends in Neurosciences, 16(10):403-409 (1993). Selkoe, D.J., "Imaging Alzheimer's Amyloid," Nat. Biotech., 18:823-824 (2000). Selkoe, Dennis J., "Alzheimer's Disease: Genotypes, Phenotype, and Treatments," Science, 275:630-631 (1997). Selkoe, Dennis J., "Amyloid Protein and Alzheimer'Disease . . . ," Scientific American, pp. 68-78 (Nov., 1991. Selkoe, Dennis J., "In the Beginning . . . ," Nature, 354:432-433 (1991). Selkoe, The cell biology of beta-amyloid precursor protein and presenilin In Alzehimer's disease. Trends Cell Biol. 8(11):447-53 (1995). Selkoe, Dennis J., "The Molecular pathology of Alzheimer's Disease," Neuron, 6:487-498 (1991). Seubert et al., "Isolation and quantification of soluble Alzheimer's .beta.-peptide from biological fluids," Nature, 359:325-327 (1992). Shiosaka, S., "Attempts to make models for Alzheimer's disease," Neuroscience Res., 13:237-258 (1992). Sigmund, "Viewpoint: Are Studies in Genefically Altered Mice Out of Control," Arterioscler Thromb Vasc Biol., 20:1425-1429 (2000). Sigurdsson, et al. in vivo reversal of amyloid-beta lesions in rat brain. J Neuropathol Exp Neurol. 59(1):11-17 (2000). Sinha, et al. Recent advances in the understanding of the processing of APP to beta amyloid peptide. Ann N Y Acad Sci. 920:206-8 (2000). Small, et al. Alzheimer's disease and Abeta toxicity:from top to bottom, Nat. Rev Neurosol. 2(8):595-8 (2001). Smits et al., "Prion Protein and Scraple Susceptibility," Vet. Quart., 19(3): 101-105 (1997). Solomon and Goldstein, "Modulation of The Catalytic Pathway of Carboxypeptidase A by Conjugation with Polyvinyl Alcohols," Adv. Mol. Cell Biology, 15A:33-45 (1996). Solomon et al., "Disaggregation of Alzheimer .beta.-amyloid by site-directed mAb," PNAS USA, 94:4109-4112 (1997). Solomon et al., "Monclonal antibodies Inhibit in vitro fibrillar aggregation of the Alzheimer .beta.-amyloid peptide," PNAS USA, 93:452-455 (1998). Soto, et al. Beta sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidoaia: implications for Alzheimer's therapy. Nat Med. 4(7):822-6 (1998). Southwick et al., "Assessment of Amyloid .beta. protein in Cerebrospinal fluid as an Aid in the Diagnosis of Alzheimer's Disease," J. Neurochemistry, 66:259-265 (1996). St. George-Hyslop, Peter H. and David A. Westaway, :Antibody clears senile plaques, Nature. 40:116-117 (1999). Stoute et al., "A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against Plasmodium falciparum Melaria", N. Engl. J. Med., 336(2): 86-91 (1997). Sturchler-Pierrat et al., "Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology," PNAS, 94: 13287-13292 (1997). Szendrei, et al., "The effects of aspartic acid-bond isomerization on in vitro properties of the amyloid .beta.-peptide as modeled with N-terminal decapeptide fragments," Int. J. Peptide Protein Res., 47:289-295 (1996). Tanaka et al., "NC-1900, an active fragment analog of arginine vasopressin, Improves learning and memory deficits induced by beta-amyloid protein in rats," European J. Pharmacology, 352:135-142 (1998). Thorsett, E.D. and L.H, Latimer, "Therapeutic approaches to Alzheimer's disease," Curr. Op. in Chem. Biology, 4:377-382 (2000). Tjernberg et al., "Arrest of .beta.-amyloid fibril formation by a pentapeptide ligand," Journal of Biological Chemistry, 271:8545-8548 (1996). Trieb et al., "Is Alzheimer beta amyloid precursor protein (APP) an autoantigen? Peptides corresponding to parts of the APP sequences atimulate T lymphocytes in normals, but not in patients with Alzheimer's disease," Immunobiology, 191(2-3):114-115 Abstract C.37, (1994). Van Gool. et al., "Concentrations of amyloid-.beta. protein in cerebrospinal fluid Increases with age in patients free from neurodegenerative disease," Neuroscience Letters, 172:122-124 (1994). Vehmas, et al. beta-Amyloid peptide vaccination results in marked changes in serum and brain Abeta levels in APPswe/PS1 DeltaE9 mice, as detected by SELDI-TOF-based ProteinChip.RTM. technology. DNA Cell Biol. (11):713 21 (2001). Verbeek et al., "Accumulation of Intercellular Adhesion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease," Amer. Journ. Pathology, 144(1):104-118 (1994). Walker et al., "Labeling of Cerebral Amyloid In Vivo with a Monoclonal Antibody," J. Neuropath. Exp. Neurology, 53(4):377-383 (1994). Weiner et al., "Nasal administration of amyloid-.beta. peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease," Annals of Neurology, 48:567-579 (2000). Weiner et al., "Oral Tolerance: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens," Annu. Rev. Immunol., 12:809-837 (1994). Weissmann et al., "Bovine spongiform encephalopathy and early onset variant Creutzfeldt-Jakob disease," Curr. Opin. Neurobiol., 7:695-700 (1997). Wen, G.Y., "Alzheimer's Disease and Risk Factors," J. Food Drug Analysis, 6(2):465-476 (1998). Wengenack et al., "Targeting Alzheimer amyloid plaques in vivo," Nature Biotech., 18:868-872 (2000). Wong et al., "Neuritic Plaques and Cerebrovascular Amyloid in Alzheimer Disease are Antigenically Related," PNAS USA, 82:8729-8732 (1985). Wood et al., "Amyloid precursor protein processing and A{character pullout}42 deposition in a transgenic mouse model of Alzheimer disease," PNAS USA, 94: 1550-1555 (1997). Wu, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor," J. Clin. Invest., 100:1804-1812 (1997). Yamaguchi et al., Diffuse plaques associated with astroglial amyloid .beta. protein, possibly showing a disappearing stage of senile plaques, Acta Neuropathol., 95:217-222 (1998). Younkin, "Amyloid .beta. vaccination: reduced plaques and improved cognition," Nature Medicine, 7:18-19 (2001). Stein and Johnson, "Lack of Neurodegeneration in Transgenic Mice Overexpressing Mutant Amyloid Precursor Protein is Associated with Increased Levels of Transthyretin and Activation of Cell Survival Pathways," The Journal of Neuroscience, 22(17):7380-7388 (Sep. 1, 2002). Tennent et al., "Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer's disease and systemic amyloidosis," PNAS, 92:4299-4303 (1995). Chen, et al., "Neurodegenerative Alzheimer-like pathology in PDAPP 717V.fwdarw.F transgenic mice," Progress in Brain Research, Van Leeuwen et al. Eds, 117:327-337 (1998). Conway et al., "Acceleration of oligomerization;, not fibrillization, is a shared property of both .alpha.-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy," PNAS, 97(2):571-576 (2000). Jobling and Holmes, "Analysis of structure and function of the B subunit of cholera toxin by the use of site-directed mutagenesis," Molecular Microbiology, 5(7); 1755-1767 (1991). Masliah et al., ".beta.-Amyloid peptides enhance .alpha.-synucleln accumulation and neuronal deficits in a transgenic mouse model-linking Alzheimer's disease and Parkinson's disease," PNAS, 98(21):12245-12250 (2001). Perutz et al., "Amyloid fibers are water-filled nanotubes," PNAS,99(8):5591-5595 (2002). Skolnick and Fetrow, "From genes to protein structure and function: novel applications of computational approaches in the genomic era," Trends in Biotech, 18(1):34-39 (2000). Aguzzi et al., "Prion research: the next frontiers," Nature, 389:795-798 (1997). Akiyama et al., "Inflammation and Alzheimer's disease," Neurobiology of Aging 21:383-421 (2000). Akiyama et al., "Occurrence of the Diffuse Amyloid .beta.-Protein (A.beta.) Deposits With Numerous A.beta.- Containing Glial Cells in the Cerebral Cortax of Patients With Alzheimer's Disease," Gila, 25:324-331 (1999). Benjamini and Leskowitz, from Immunology A Short Course, Second Edition, Chapter 4, Antibody Structure, pp. 49-65, 1991, published by Wiley-Liss, Inc. New York, New York. Check, "Battle of the Mind," Nature, 422:370-372 (Mar. 2003). Diomede et al., "Activation effects of a prion protein fragment [PrP-(106-126)] on human leucocytes," Biochem. J., 320:53-570 (1996). Dodart, "Immunotherapy for Alzheimer's disease: will vaccination work?" Trends in Molecular Medicine, 9(3):85-87 (2003). Fratutschy et al., "Effects of injected Alzheimer .beta.-amyloid cores in rat brain," PNAS, 88:8362-8356 (1991). Furlan et al., "Vaccination with amyloid-.beta. peptide induces autoimmune encephalomyelitis in C57/BL6 mice," Brain, 126:285-291 (2003). Goldfarb et al., "The Transmissible Spongiform Encephalopathies," Ann. Rev. Med., 48:57-65 (1995). Goldsteins et al., "Goldsteins et al., Exposure of cryptic epitopes on transthyrelin only in amypoid and in amyloidogenic mutants," PNAS, 96:3108-3113 (1999). Jakes et al., "Characterisation of an Antibody Relevant to the Neuropathology of Alzheimer Disease," Alzheimer Disease and Associated Disorders, 9(1):47-51, Raven Press, Ltd., New York (1995). Johnstone et al., Nuclear and Cytoplasmic Localization of the .beta.-Amyloid Peptide (1-43) in Transfected 293 Cells, Biochemical and Biophysical Research Communications, 220:710-718 (1996). Jorbeck et al., "Artificial Salmonella Vaccines: Salmonella typhimurium O-antigen-Specific Oligosaccharide-Protein Cojugates Elicit Opsonizing Antibodies that Enhance Phagocylosts," Infection and Immunity, May:497-502 (1981). Kovacs et al., "Mutations of the Prion Protein Gene Phenotypic Spectrum," J. Neurol., 249:1567-1582 (2002). Monsonego et al., "Immune hyporesponsiveness to amyloid .beta.-peptide in amyloid precursor protein transgenic mice: Implications for the pathogenesis and treatment of Alzheimer's disease," PNAS, 98(18):10273-10278 (2001). Munch et al., "Potentional neurotoxic inflammatory response to A.beta. vaccination in humans," (2002) J. Neural Transm., 109:1081-1087. Munson ed., "Principals of Pharmacology: Basic Concepts & Clinical Applications," (1995), 47-48, Chapman & Hall, New York, New York. Mutschler et al., "Drug Actions: Basic Principles and Therapeutic Aspects," (1995) 7, 11-12, medpharm Scientific Publishers, Stuttgart, Germany. Nicoll et al., "Neuropathology of human Alzheimer's disease after Immunization with amyloid-.beta. peptide: a case report," Nature Medicine, 9(4):448-452 (Apr. 2003). Palha et al., "Antibody recognition of amyloidogenic transthyretin variants in serum of patients with familial amyloidiotic polyneuropathy, " J. Mol. Med., 7:703-707 (2001). Pan et al., "Antibodies to .beta.-Amyloid Decreases the Blood-to-Brain Transfer of .beta.-Amyloid Peptide," Exp. Biol. Med., 227(8):609-615 (2002). Prusiner et al., "Ablation of the prion protein (PrP) gene in mice prevents scraple and facilitates production of anti-PrP antibodies," PNAS, 90:10606-10612 (1993). Sigurdsson et al., "Anti-prior antibodies for prophytaxis following prion exposure in mice," Neurosciences Letters, 336:185-187 (2003). Sigurdsson et al., "Immunization Delays the Onset of Prion Disease in Mice," American Journal of Pathology, 101:13-17 (2002). Sigurdsson et al., "A safer vaccine for Alzheimer's disease?, " Neurobiology of Aging, 23:1001-1008 (2002). Sipe, "Amyloidosis," Annu. Rev. Biochem., 61:947-975 (1992). Spooner et al., "The generation and characterization of potentially therapeutic A.beta. antibodies in mice: differences according to strain and Immunization protocol," Vaccine. 21:290-297 (2002). Su et al., "Intravascular infusions of soluble .beta.-amyloid compromise the blood-brain barrier, activate CNS Glial cells and Induce peripheral hemorrhage," Brain Research, 818:105-107 (1999). Tal et al., "Complete Freund's Adjuvant Immunization Prolongs Survival in Experimental Prion Disease in Mice," Journal of Neuroscience Research, 71:286-290 (2003). Tan et al., "Amyloidosis," Histopathology, 25:403-414 (1994). Tsuzuki et al., "Amyloid .beta. protein in rat soleus in choroquine-induced myopthy using end-specific antibodies for A62 40 and A.beta.42: Immunohistochemical evidence for amyloid .beta. protein," Neuroscience Letters, 2002:77-80 (1995). Weldon et al., "Neurotoxicity of A.beta. Peptide: Confocal Imaging of Cellular Changes Induced by--Amyloid in Rat CNS In Vivo," Society for Neuroscience Abstracts, 22(Part 1) (1996). **** Wisniewski et al., "Therapeutics in Alzheimer's and Prion Diseases," Biochemical Society Transactions, 30(4):-574-587 (2002). |
| PATENT PARENT CASE TEXT | This data is not available for free |
| PATENT CLAIMS |
What is claimed is: 1. A pharmaceutical composition comprising a chimeric or humanized antibody that specifically binds to an epitope within residues 1-10 of A.beta. and a pharmaceutical carrier. 2. The pharmaceutical composition of claim 1, wherein the antibody specifically binds to an epitope within residues 1-6 of A.beta.. 3. The pharmaceutical composition of claim 1, wherein the antibody specifically binds to an epitope within residues 1-5 of A.beta.. 4. The pharmaceutical composition of claim 1, wherein the antibody specifically binds to an epitope within residues 1-4 of A.beta.. 5. The pharmaceutical composition of claim 1, which is a sustained release composition. 6. The pharmaceutical composition of claim 1, wherein the isotype of the antibody is human IgG1. 7. The pharmaceutical composition of claim 1, wherein the carrier is a physiologically acceptable diluent for parenteral administration. 8. A diagnostic kit, comprising a chimeric or humanized antibody that specifically binds to an epitope within residues 1-10 of A.beta.. 9. The diagnostic kit of claim 8, wherein the antibody binds to an epitope within residues 4-10 of A.beta.. 10. The diagnostic kit of claim 8, wherein the antibody binds to an epitope within residues 8-10 of A.beta.. 11. The diagnostic kit of claim 8, wherein the antibody is labeled. 12. The diagnostic kit of claim 8, wherein the antibody is labeled with a paramagnetic label. -------------------------------------------------------------------------------- |
| PATENT DESCRIPTION |
TECHNICAL FIELD The invention resides in the technical fields of immunology and medicine. BACKGROUND OF THE INVENTION Alzheimer's disease (AD) is a progressive disease resulting in senile dementia See generally Selkoe, TINS 16, 403-409 (1993); Hardy et al., WO 92/13069; Selkoe, J. Neuropathol. Exp. Neurol. 53, 438-447 (1994); Duff et al., Nature 373, 476-477 (1995); Games et al., Nature 373, 523 (1995). Broadly speaking, the disease falls into two categories: late onset, which occurs in old age (65+ years) and early onset, which develops well before the senile period, i.e., between 35 and 60 years. In both types of disease, the pathology is the same but the abnormalities tend to be more severe and widespread in cases beginning at an earlier age. The disease is characterized by at least two types of lesions in the brain, senile plaques and neurofibrillary tangles. Senile plaques are areas of disorganized neuropil up to 150 .mu.m across with extracellular amyloid deposits at the center visible by microscopic analysis of sections of brain tissue. Neurofibrillary tangles are intracellular deposits of microtubule associated tau protein consisting of two filaments twisted about each other in pairs. The principal constituent of the plaques is a peptide termed A.beta. or .beta.-amyloid peptide. A.beta. peptide is an internal fragment of 39-43 amino acids of a precursor protein termed amyloid precursor protein (APP). Several mutations within the APP protein have been correlated with the presence of Alzheimer's disease. See, e.g., Goate et al., Nature 349, 704) (1991) (valine.sup.717 to isoleucine); Chartier Harlan et al. Nature 353, 844 (1991)) (valine.sup.717 to glycine); Murrell et al., Science 254, 97 (1991) (valine.sup.717 to phenylalanine); Mullan et al., Nature Genet. 1, 345 (1992) (a double mutation changing lysine.sup.595 -methionine.sup.596 to asparagine.sup.595 -leucine.sup.596). Such mutations are thought to cause Alzheimer's disease by increased or altered processing of APP to A.beta., particularly processing of APP to increased amounts of the long form of A.beta. (i.e., A.beta.1-42 and A.beta.1-43). Mutations in other genes, such as the presenilin genes, PS1 and PS2, are thought indirectly to affect processing of APP to generate increased amounts of long form A.beta. (see Hardy, TINS 20, 154 (1997)). These observations indicate that A.beta., and particularly its long form, is a causative element in Alzheimer's disease. McMichael, EP 526,511, proposes administration of homeopathic dosages (less than or equal to 10.sup.-2 mg/day) of A.beta. to patients with preestablished AD. In a typical human with about 5 liters of plasma, even the upper limit of this dosage would be expected to generate a concentration of no more than 2 pg/ml. The normal concentration of A.beta. in human plasma is typically in the range of 50-200 pg/ml (Seubert et al., Nature 359, 325-327 (1992)). Because EP 526,511's proposed dosage would barely alter the level of endogenous circulating A.beta. and because EP 526,511 does not recommend use of an adjuvant, as an immunostimulant, it seems implausible that any therapeutic benefit would result. By contrast, the present invention is directed inter alia to treatment of Alzheimer's and other amyloidogenic diseases by administration of fragments of A.beta., or antibody to certain epitopes within A.beta. to a patient under conditions that generate a beneficial immune response in the patient The invention thus fulfills a longstanding need for therapeutic regimes for preventing or ameliorating the neuropathology and, in some patients, the cognitive impairment associated with Alzheimer's disease. This application is related to International Application No. PCT/US00/14810 filed May 26, 2000, Publication No. WO 00/72880; and, International Application No. PCT/US98/25386, filed Nov. 30, 1998, Publication No. WO 99/27944; both of which are incorporated by reference in their entirely for all purposes. SUMMARY OF THE CLAIMED INVENTION In one aspect, the invention provides methods of preventing or treating a disease associated with amyloid deposits of A.beta. in the brain of a patient. Such diseases include Alzheimer's disease, Down's syndrome and cognitive impairment. The latter can occur with or without other characteristics of an amyloidogenic disease. Some methods of the invention entail administering an effective dosage of an antibody that specifically binds to a component of an amyloid deposit to the patient. Such methods are particularly useful for preventing or treating Alzheimer's disease in human patients. Some methods entail administering an effective dosage of an antibody that binds to A.beta.. Some methods entail administering an effective dosage of an antibody that specifically binds to an epitope within residues 1-10 of A.beta.. In some methods, the antibody specifically binds to an epitope within residues 1-6 of A.beta.. In some methods, the antibody specifically binds to an epitope within residues 1-5 of A.beta.. In some methods, the antibody specifically binds to an epitope within residues 1-7 of A.beta.. In some methods, the antibody specifically binds to an epitope within residues 3-7 of A.beta.. In some methods, the antibody specifically binds to an epitope within residues 1-3 of A.beta.. In some methods, the antibody specifically binds to an epitope within residues 1-4 of A.beta.. In some methods, the antibody binds to an epitope comprising a free N-terminal residue of A.beta.. In some methods, the antibody binds to an epitope within residues of 1-10 of A.beta. wherein residue 1 and/or residue 7 of A.beta. is aspartic acid. In some methods, the antibody specifically binds to A.beta. peptide without binding to full-length amyloid precursor protein (APP). In some methods, the isotype of the antibody is human IgG1. In some methods, the antibody binds to an amyloid deposit in the patient and induces a clearing response against the amyloid deposit. For example, such a clearing response can be effected by Fc receptor mediated phagocytosis. The methods can be used on both asymptomatic patients and those currently showing symptoms of disease. The antibody used in such methods can be a human, humanized, chimeric or nonhuman antibody and can be monoclonal or polyclonal. In some methods, the antibody is prepared from a human immunized with A.beta. peptide, which human can be the patient to be treated with antibody. In some methods, the antibody is administered with a pharmaceutical carrier as a pharmaceutical composition. In some methods, antibody is administered at a dosage of 0.0001 to 100 mg/kg, preferably, at least 1 mg/kg body weight antibody. In some methods, the antibody is administered in multiple dosages over a prolonged period, for example, of at least six months. In some methods, the antibody is administered as a sustained release composition. The antibody can be administered, for example, intraperitoneally, orally, subcutaneously, intracranially, intramuscularly, topically, intranasally or intravenously. In some methods, the antibody is administered by administering a polynucleotide encoding at least one antibody chain to the patient. The polynucleotide is expressed to produce the antibody chain in the patient. Optionally, the polynucleotide encodes heavy and light chains of the antibody. The polynucleotide is expressed to produce the heavy and light chains in the patient In some methods, the patient is monitored for level of administered antibody in the blood of the patient. In another aspect, the invention provides methods of preventing or treating a disease associated with amyloid deposits of A.beta. in the brain of patient. For example, the methods can be used to treat Alzheimer's disease or Down's syndrome or cognitive impairment. Such methods entail administering fragments of A.beta. or analogs thereof eliciting an immunogenic response against certain epitopes within A.beta.. Some methods entail administering to a patient an effective dosage of a polypeptide comprising an N-terminal segment of at least residues 1-5 of A.beta., the first residue of A.beta. being the N-terminal residue of the polypeptide, wherein the polypeptide is free of a C-terminal segment of A.beta.. Some methods entail administering to a patient an effective dosage of a polypeptide comprising an N-terminal segment of A.beta., the segment beginning at residue 1-3 of A.beta. and ending at residues 7-11 of A.beta.. Some methods entail administering to a patient an effective dosage of an agent that induces an immunogenic response against an N-terminal segment of A.beta., the segment beginning at residue 1-3 of A.beta. and ending at residues 7-11 of A.beta. without inducing an immunogenic response against an epitope within residues 12-43 of A.beta.43. In some of the above methods, the N-terminal segment of A.beta. is linked at its C-terminus to a heterologous polypeptide. In some of the above methods, the N-terminal segment of A.beta. is linked at its N-terminus to a heterologous polypeptide. In some of the above methods, the N-terminal segment of A.beta. is linked at its N and C termini to first and second heterologous polypeptides. In some of the above methods, the N-terminal segment of A.beta. is linked at its N terminus to a heterologous polypeptide, and at its C-terminus to at least one additional copy of the N-terminal segment. In some of the above methods, the heterologous polypeptide and thereby a B-cell response against the N-terminal segment. In some of the above methods, the polypeptide further comprises at least one additional copy of the N-terminal segment. In some of the above methods, the polypeptide comprises from N-terminus to C-terminus, the N-terminal segment of A.beta., a plurality of additional copies of the N-terminal segment, and the heterologous amino acid segment. In some of the above methods, the N-terminal segment consists of A.beta.B1-7. In some of the above methods, the N-terminal segment consists of A.beta.3-7. In some methods, the fragment is free of at least the 5 C-terminal amino acids in A.beta.43. In some methods, the fragment comprises up to 10 contiguous amino acids from A.beta.. Fragments are typically administered at greater 10 micrograms per dose per patient. In some methods, the fragment is administered with an adjuvant that enhances the immune response to the A.beta. peptide. The adjuvant and fragment can be administered in either order or together as a composition. The adjuvant can be, for example, aluminum hydroxide, aluminum phosphate, MPL.TM., QS-21 (Stimulon.TM.) or incomplete Freund's adjuvant. The invention further provides pharmaceutical compositions comprising fragments of A.beta. or other agents eliciting immunogenic response to the same epitopes of A.beta., such as described above, and an adjuvant. The invention also provides pharmaceutical compositions comprising any of the antibodies described above and a pharmaceutically acceptable carrier. In another aspect, the invention provides methods of screening an antibody for activity in treating a disease associated with deposits of A.beta. in the brain of a patient (e.g., Alzheimer's disease). Such methods entail contacting the antibody with a polypeptide comprising at least five contiguous amino acids of an N-terminal segment of A.beta. beginning at a residue between 1 and 3 of A.beta., the polypeptide being free of a C-terminal segment of A.beta.. One then determines whether the antibody specifically binds to the polypeptide, specific binding providing an indication that the antibody has activity in treating the disease. In another aspect, the invention provides methods of screening an antibody for activity in clearing an antigen-associated biological entity. Such methods entail combining the antigen-associated biological entity and the antibody and phagocytic cells bearing Fc receptors in a medium. The amount of the antigen-associated biological entity remaining in the medium is then monitored. A reduction in the amount of the antigen-associated biological entity indicates the antibody has clearing activity against the antigen-associated biological entity. The antigen can be provided as a tissue sample or in isolated form. For example, the antigen can be provided as a tissue sample from the brain of an Alzheimer's disease patient or a mammal animal having Alzheimer's pathology. Other tissue samples against which antibodies can be tested for clearing activity include cancerous tissue samples, virally infected tissue samples, tissue samples comprising inflammatory cells, nonmalignant abnormal cell growths, or tissue samples comprising an abnormal extracellular matrix. In another aspect, the invention provides methods of detecting an amyloid deposit in a patient. Such methods entail administering to the patient an antibody that specifically binds to an epitope within amino acids 1-10 of A.beta., and detecting presence of the antibody in the brain of the patient. In some methods, the antibody binds to an epitope within residues 4-10 of A.beta.. In some methods, the antibody is labelled with a paramagnetic label and detected by nuclear magnetic resonance tomography. The invention further provides diagnostic kits suitable for use in the above methods. Such a kit comprises an antibody that specifically binds to an epitope with residues 1-10 of A.beta.. Some kits bear a label describing use of the antibody for in vivo diagnosis or monitoring of Alzheimer's disease. |
| PATENT EXAMPLES | available on request |
| PATENT PHOTOCOPY | available on request |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |